Live · Librarian-verified
Compounded GLP-1 Legal Status
The legality of compounded semaglutide and tirzepatide has tightened sharply since both drugs came off the FDA shortage list. This tracks what is — and isn't — permitted now.
4
Points tracked
2
Points current
2h
Since last verification
2
Points expired
Point statusCurrent — confirmed within its check windowChanged — the underlying fact movedPending — re-check queuedExpired — past its window, treat as unverified
Inside a tracker
Restricted · 4 points| Tracked statement | Status | Source | Last confirmed |
|---|---|---|---|
| Semaglutide shortage status — Removed from FDA shortage list (Feb 2025)With semaglutide off the shortage list, the legal basis for mass compounding lapsed. | Expired | — | Nov 5, 2026 |
| Tirzepatide shortage status — Removed from FDA shortage list (Dec 2024) | Expired | — | Nov 5, 2026 |
| Compounding of semaglutide/tirzepatide — Broadly no longer permitted for mass production — Limited case-by-case compounding may remain for documented medical need under 503A; mass compounding ended.Limited case-by-case compounding may remain for documented medical need under 503A; mass compounding ended. | Current | — | Oct 30, 2026 |
| Retatrutide / cagrilintide compounding — Not permitted — Not components of FDA-approved drugs.Not components of FDA-approved drugs. | Current | — | Oct 30, 2026 |
Expired does not mean false — it means nobody has confirmed it recently enough for us to stand behind it. 2 points here are past their window and are queued for review.
How we keep this current
Our AI Librarian periodically re-checks each line against primary sources — FDA notices, manufacturer announcements, and clinical-trial registries — and re-stamps the "last verified" date above. Fast-moving regulatory facts can still change between checks; always confirm against the linked primary source before relying on any single line.